Hydroxychloroquine has unique immunomodulatory properties and an attractive adverse effect profile. Over the past 10 years, research has led to significant updates in clinical recommendations concerning the optimal use of hydroxychloroquine and monitoring of patients taking it. We discuss updated recommendations concerning hydroxychloroquine daily dosing, retinopathy screening, serologic monitoring, use in smokers, use in pregnant women, and adverse effect risk and monitoring. This review can hopefully serve as an aid to dermatologists and help ensure they continue using hydroxychloroquine safely and effectively. ( J Am Acad Dermatol 2017;76:1176-82.) Key words: adverse effects; hydroxychloroquine; lupus erythematosus; monitoring; recommendations; retinopathy screening; whole blood levels.
S ince hydroxychloroquine's (HCQ) introduction in 1955, its uses in medicine and dermatology have persistently expanded (Table I) . Using HCQ to treat inflammatory and rheumatic skin diseases may allow for the reduction in the use of glucocorticoids and other immunosuppressive medications with more concerning adverse effects (AEs). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] HCQ has been found to have antithrombotic, antifibrotic, antidyslipidemic, and antihyperglycemic properties, [1] [2] [3] [4] [5] 17, [20] [21] [22] and substantial changes have been made in its clinical recommendations during the past decade. This article provides a focused update concerning HCQ recommendations arising in dermatologic practice (Table II) .
METHODS
A PubMed search for hydroxychloroquine from January 2005 to June 2016 was conducted, revealing 1929 articles. These articles were evaluated by reviewing titles and abstracts. Those containing information of high clinical importance to dermatologists were examined completely and are referenced if information was extracted for this review.
RESULTS

Dosing
It has classically been that recommended daily doses not exceed 6.5 mg/kg ideal body weight (IBW) or 400 mg daily, whichever is lower. Using IBW and not actual body weight (ABW) for daily dosing was rationalized because HCQ does not accumulate well in fat. ABW dosing was thought to potentially increase the amount accumulated in tissues and increase AE risk, namely retinopathy.
New HCQ-dosing recommendations were proposed after a study examining the risk for HCQ-induced retinal pigment epithelium WB-HCQ: whole blood hydroxychloroquine levels retinopathy found optimal doses would be #5.0 mg/kg ABW. 23 The new recommendations are thought to be similar to the previous IBW-dosing regimen given most patients are overweight and not perfectly adherent, but they are particularly important for thin patients. Although #5.0 mg/kg ABW daily dosing in thin patients is recommended, appropriate dosing in obese patients is unclear. In contrast with IBW dosing, ABW dosing might result in relative overdosing of obese patients (Table II) . 24 Pending further research, it seems reasonable to calculate 5.0 mg/kg ABW and 6.5 mg/kg IBW doses in obese patients and prescribe the lowest of the 2, with a 400 mg/day maximum.
Because HCQ has a long elimination half-life, alternate-day dosing can be used to optimize daily dose. For example, 400 mg alternating with 200 mg daily can be used to reach effective daily dosing of 300 mg/day. In addition, because stable blood concentrations are not reached for 3-6 months, loading during the initial 1-2 months with daily doses #1200 mg can be used to accelerate response, with the caveat that this might increase gastrointestinal intolerance.
2,24-26
Monitoring response
High-performance liquid chromatography is routinely available for quantifying mean whole blood HCQ (WB-HCQ) levels. Measuring WB-HCQ levels is becoming increasingly valued because of its correlation with systemic (SLE) and cutaneous (CLE) lupus erythematosus severity; patients achieving significant LE disease activity decreases and remission have significantly higher WB-HCQ levels than those with persistently high disease activity. [27] [28] [29] Measuring WB-HCQ levels also allows identification of noncompliant patients, which is not trivial. 30 Noncompliance lacks correlation with education and income. Noncompliant patients were found unexpectedly because many of them routinely attended clinic appointments, received routine ophthalmology examinations, and were not forthcoming about noncompliance. 30 Furthermore, reeducating patients about HCQ benefits and safety resulted in increased WB-HCQ levels and thus improved compliance, supporting that monitoring is cost-effective. [30] [31] [32] An important question is how best to treat compliant patients with both inadequate WB-HCQ levels and inadequate responses. This was addressed in a study involving refractory CLE patients with low WB-HCQ levels (\750 ng/ml) despite most taking 400 mg daily. 33 By increasing HCQ daily doses (to a median of 9.8 mg/kg ABW) all patients achieved adequately increased WB-HCQ levels (median 1187 ng/ml) and statistically significant improvements in CLE disease activity. Doses were decreased back to 400 mg daily for these patients; however, some subsequently experienced disease relapse and required transient HCQ increases again. Only one patient developed preclinical retinopathy, but median cumulative HCQ dose in this cohort was lower than expected for retinopathy (523 g). Determining whether this strategy is safe long-term will require additional research, especially because patients taking 800-1000 mg HCQ daily developing rapid-onset retinopathy have been reported. 34, 35 Overall, studies suggest clinicians should not consider that HCQ treatment failed without measuring WB-HCQ levels. A limitation of this approach is a lack of a current standard effective WB-HCQ level, although median WB-HCQ levels in cohorts demonstrating significant improvement and remission have typically been [750 ng/ml and levels [500 ng/ml can be considered adherent. [27] [28] [29] 33 Also, although it seems appropriate to extrapolate findings in LE cohorts for now, research assessing utility of measuring WB-HCQ levels in patients with other diseases is needed.
Efficacy in smokers
The idea that smoking interferes with HCQ efficacy was first reported in 1993 and is wellknown throughout the dermatology community. 36 Research studies, however, have shown mixed results. Several found no significant difference in HCQ response between smokers and nonsmokers, no increased prevalence of smokers in treatment failure populations versus improved and remission populations, and no smoking effect on WB-HCQ levels. 9, 29, 37 A study examining smoking influence on antimalarial therapy in CLE patients found
Hydroxychloroquine is a medication with unique immunomodulatory properties and broad applicability in dermatologic practice. Implementing these updated recommendations will help ensure dermatologists continue using hydroxychloroquine safely and effectively.
statistical significance for chloroquine, but not HCQ. 38 Alternatively, a recent meta-analysis found a pooled odds ratio for CLE response of 0.53 for smokers versus nonsmokers. 39 If smoking decreases HCQ efficacy, the mechanism is not understood. One hypothesis is that nicotine increases toll-like receptor 9 responsiveness to agonists, which might lead to decreased HCQ-induced toll-like receptor 9 inhibition and increased type I interferon cytokine production. 40, 41 This could explain how HCQ could be less efficacious in smokers despite similar WB-HCQ levels as nonsmokers and would correlate with reports of CLE patients improving after smoking cessation. 42 Other potential mechanisms could include nicotine's phototoxic properties, its ability to upregulate matrix metalloproteinases, or the contribution of other confounding factors. 41, 42 Although effects on HCQ efficacy is unclear, smoking is well-known to aggravate CLE. 43, 44 Thus, it seems prudent for dermatologists to educate patients about negative smoking effects on CLE activity and potential effects on HCQ efficacy. Smoking currently should not preclude dermatologists from prescribing HCQ. Even if a partial response occurs, this might help minimize doses of immunosuppressive medications required to control disease.
Use in pregnancy
HCQ treatment during pregnancy has been widely studied in LE patients. There is no evidence HCQ results in congenital defects, stillbirth, prematurity, low birth weight, fetal death, or retinopathy.
2,45-48 Importantly, chloroquine can cause fetal retinopathy and should not be administered during pregnancy. A recent metaanalysis found an association between HCQ use and spontaneous abortion risk, but authors could not rule out underlying disease as causal. 48 In addition, pregnant SLE patients who stop taking HCQ have increased LE activity, more frequent and severe LE flares, and require more prednisone. 46, 47 All of these can be detrimental to developing fetuses. Although possible association with spontaneous abortion needs further evaluation, expert opinion recommendations are that HCQ can be continued during pregnancy and lactation. 46, 47 
Monitoring for retinopathy
Retinopathy arguably represents the most feared HCQ-induced complication. Mechanisms underlying HCQ-induced retinopathy are not understood, but HCQ accumulation in the retinal pigment epithelium (RPE) might contribute to the condition. Classically, HCQ-induced retinopathy is characterized by bulls-eye maculopathy, whereby examination reveals a ring of RPE depigmentation that spares a foveal island (Fig 1) . 24 However, recent research suggests damage patterns might vary with ethnicity. 28, 49, 50 Recently, it was shown that HCQ-induced retinopathy prevalence is higher than previously thought (7.5%). 23 This was found after 2361 patients who took HCQ [5 years were evaluated with 10-2 visual fields or spectral-domain optical coherence tomography. 23 The most critical risk factor for retinopathy is daily dose; those exceeding 5 mg/kg ABW daily had 10% retinopathy risk within 10 years and ;40% risk after 20 years. Alternatively, those taking 4-5 mg/kg daily had \2% risk within 10 years and 20% risk after 20 years. 23, 50 Avoiding[5.0 mg/kg HCQ daily also reduces cumulative dose, which might be an additional retinopathy risk factor. [23] [24] [25] Risk is low during the first 5 years but increases sharply after 5-7 years. Retinopathy mostly occurs with cumulative doses[1000 g (reached after 7 years of 400 mg daily).
Additional HCQ-induced retinopathy risk factors include renal disease, retinal disease, macular disease, and concurrent tamoxifen use. 23 Maculopathy is a relative HCQ contraindication because it can mask early retinopathy and makes screening difficult-to-impossible. 24, 25, 50 Revised HCQ-induced retinopathy screening recommendations were published by the American Academy of Ophthalmology in 2011 and 2016. 24, 49 Screening goals are to recognize abnormalities 49 These new screening guidelines recommend baseline examination be performed within the first year of treatment. Thus, HCQ can be initiated before baseline ophthalmologic examination, which is important since clinical efficacy takes 3-6 months. Annual screening is recommended to begin only after 5 years of HCQ use. 24, 49 Earlier or more frequent screening is justified in high-risk patients. It remains unclear whether screening can actually prevent damage, though, and studies following patients longitudinally for retinopathy progression are needed to assess the true value of current recommendations.
Strategies are needed to ensure retinopathy screenings are performed. One study found that \50% of patients taking antimalarials had baseline screening within year 1, and 33% of high-risk patients had no testing during the entire 5-year study. 51 Engaging staff in reminding patients about examinations or sending automatic reminders within electronic medical records systems are potential strategies to improve adherence.
If exam abnormalities are due to HCQ, discontinuation is typically recommended. If benefits of continuing HCQ outweigh risks when early retinopathy is detected, HCQ may be continued. However, ophthalmologic monitoring every 3 months is recommended in such cases.
Adverse effects and laboratory monitoring
Common HCQ AEs include gastrointestinal symptoms like nausea, vomiting, and diarrhea. These are typically transient or resolve by decreasing daily dose. Cutaneous blue-gray hyperpigmentation is also relatively common, occurring in #25% of patients. In a study examining HCQ-induced pigmentation in SLE patients, 92% of reported lesions were preceded by ecchymoses and 95% had $1 condition predisposing to bruising, suggesting easy bruising might predispose these patients to HCQ-induced hyperpigmentation. 52 Rare AEs include hemolytic anemia with glucose-6-phosphate dehydrogenase (G6PD) deficiency and cutaneous reactions. Importantly, hemolysis with G6PD deficiency does not occur at recommended HCQ doses and routine G6PD-deficiency testing is not recommended. 2, 20 The most common cutaneous reactions are morbilliform and psoriasiform eruptions. Although uncommon, HCQ is among the most frequently implicated medications causing acute generalized exanthematous pustulosis, with Optimal patient dosing for is #5.0 mg/kg of actual (real) body weight or 400 mg daily, whichever is lower, for most patients.* Whole blood HCQ levels should be checked in patients not adequately responding, with goals for efficacy being [750 ng/ml and for compliance being [500 ng/ml. Smokers should be educated about benefits of cessation, but effects of smoking on HCQ therapy are unclear and HCQ treatment should still be attempted in lieu of other, more potent immunosuppressive medications. Expert opinion suggests HCQ can be continued during both pregnancy and lactation in patients felt to be benefiting from it. The biggest risk factor for HCQ ocular toxicity is daily dose, with safe dosing believed to be 4-5 mg/kg. Caution should be exercised when considering HCQ use in patients with pre-existing maculopathy or renal disease (50% reduction in renal function correlates with 2x retinopathy risk), long-term HCQ users, and women concurrently taking tamoxifen (increases retinopathy risk about fivefold). Hepatic disease and older age were thought to be retinopathy risk factors, but this was recently disputed. Baseline screening for HCQ-induced ocular toxicity should be performed within the 1st year of treatment (implying HCQ can be started prior to baseline screening). Annual ocular toxicity screening is recommended to begin only after 5 years of use unless patients are considered high-risk or develop ophthalmologic symptoms. Amsler grids are no longer appropriate for screening. Appropriate ocular toxicity testing should include 10e2 visual field testing and spectral domain ocular coherence tomography. Bruising may be a risk factor for the development of HCQ-induced hyperpigmentation.
ABW, Actual body weight; HCQ, hydroxychloroquine; IBW, ideal body weight. *Similar studies for chloroquine have not been performed, but 5.0 mg/kg HCQ would be equivalent to 2.3 mg/kg chloroquine. Ideal dosing is unclear for obese patients. For example, maximum daily dosing for a woman 592 99 and 164 lbs (a body mass index of 30 implying obesity per National Institutes of Health guidelines) would be 372 mg based on \5.0 mg/kg ABW and 325 mg based on \6.5 mg/kg IBW (;50.1 kg). This is a significant difference and may have implications concerning ocular toxicity risk over time.
lag time between HCQ initiation and onset of the condition typically 11-22 days. 53 A recent systematic review found insufficient evidence to either refute or support HCQ contributing to psoriasis or psoriasis flares. 54 HCQ-induced myopathy is rare and can affect skeletal and cardiac muscle. Cardiac involvement presents as restrictive cardiomyopathy or conduction abnormalities. 20, 55 Recovery after HCQ withdrawal is variable and death can occur. If suspected, muscle biopsy should be performed because HCQ myopathy has unique histologic characteristics. 55, 56 No cardiotoxicity screening guidelines exist, but annual electrocardiograms have been suggested.
HCQ-induced blood dyscrasias, including agranulocytosis, are rarely reported. [57] [58] [59] Therefore, the Plaquenil monograph recommends checking periodic blood counts (CBC). 58 There are also rare reports of HCQ-induced hepatotoxicity, which can be fatal. [60] [61] [62] Given this, and because monitoring renal function is critical for continual safe HCQ dosing, a complete metabolic panel (CMP) should be intermittently checked. Appropriate CBC and CMP monitoring intervals, however, remain poorly defined.
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